

Special Issue

Druggability of Proteins/Enzymes

Message from the Guest Editors

This Special Issue will cover all aspects of research works on druggable proteins and enzymes. The human genome encodes approximately 20,000 proteins, a handful of which are suitable for drug–protein interactions. This subgroup is defined here as the druggable proteins/enzymes with a specific affinity to bind small molecule(s) or antibodies mediating a signal transduction network involved in disease control. Suitable manuscripts address enzyme and protein activities targeted by drugs converting signal transduction from the site of interaction into specific responses inside the cell resulting, for example, in gene expression, cell division, and/or cell death. Research works of antibody-based drugs that cannot pass the plasma membrane are also welcome as they are mostly directed against protein targets on the cell surface (receptors) affecting their activities. Additional druggable proteins that are of interest include, but are not limited to, all works on transporters, G-protein coupled receptors, CD markers, nuclear receptors, voltage-gated ion channels, etc.

- drug
- antibodies
- druggable proteomics
- druggable enzymolomics

Guest Editors

Dr. Ruth Vinall

Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, USA

Dr. Simeon Kotchoni

Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, USA

Deadline for manuscript submissions

closed (15 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/104000

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).